Recalled Medicines & supplements – Current GIS Alerts 2026
Found 685 recalled products in the Medicines & supplements category. Check batch numbers, shops, and hazard information.
Common hazards in this category
All recalled products
Dexapini
A quality defect was found consisting of sediment in the form of crystals at the bottom of the bottle and a real suspicion of loss of syrup quality, related to potential disruption of antimicrobial protection and microbiological purity of the medicine, which may pose a health risk. Potential effects: infections, lack of treatment efficacy, health complications.
Korzeń Kozłka
Non‑compliance with quality requirements was found in the form of too low content of sesquiterpenic acids, which may reduce the effectiveness of the medicinal product. Potential effects: lack of or reduced therapeutic effect.
Korzeń Kozłka
A non‑compliance with quality requirements was found in the parameter of sesquiterpene acid content, which may affect the effectiveness of the product, even though no direct threat to the patient’s life or health was stated. Potential effects: lack of therapeutic efficacy.
Sunitinib Vipharm
The product does not meet quality requirements due to a negative test result for the “appearance” parameter – altered appearance of the capsule filling compared with the approved specification. Potential effects: possible non‑compliance of therapy with documentation and uncertainty regarding treatment quality.
Sunitinib Vipharm
The product does not meet its specified quality requirements due to a negative test result for the appearance parameter; the changed appearance of the capsule filling has not yet been approved in the quality specification. Potential effects: possible concern about medicine quality and a potential risk of dose non-uniformity.
Sunitinib Vipharm
The product does not meet quality requirements due to a negative test result for the appearance parameter; the altered capsule filling appearance does not match the currently registered quality specification. Potential effects: possible deviations in dosing and therapeutic effectiveness.
Inuprin Forte
The risk of impaired antimicrobial protection and microbiological purity of the medicine due to crystallization of sucrose in the syrup cannot be excluded. Potential effects: possible infections, reduced treatment efficacy, complications in patients.
Varilrix
The decision indicates the occurrence of a threat to public health and a real risk to patients’ health and life, considered by the authority as obvious. Potential effects: serious adverse reactions, risk to patients’ health and life.
Vitamina C Synteza
The identified non-compliance in the form of brown spots and discoloration on the capsule surface may affect the safety of medicinal product use; a risk to human health and life cannot be excluded. Potential effects: possible health risk, potential complications related to inadequate medicine quality.
Vitamina C Synteza
The identified non‑conformity in the form of brown spots and discolorations on the capsule surface may affect the safety of use of the medicinal product. Therefore, a risk to human health and life cannot be excluded. Potential effects: possible risk to health and complications related to improper drug action.
VBLAAST 10
The presence of particles visible to the naked eye of unidentified origin was found in the solution for injection, which creates a real danger of such particles entering the patient’s bloodstream and may lead to unpredictable, negative health effects. Potential effects: embolic complications, vascular damage, severe systemic reactions, life-threatening conditions.
VBLAAST 10
Visible particles of unidentified origin were found in the solution for injection, which creates a real risk of such particles entering the patient’s bloodstream and may lead to unpredictable, negative health effects. Potential effects: embolic complications, tissue damage, severe systemic complications.
Apap Extra
A risk of contamination of tablets with fragments of a damaged discharge valve gasket of the granulator was identified; the presence of a foreign body in a tablet may affect safety of use and pose a threat to human health and life. Potential effects: mechanical injuries of the gastrointestinal tract, choking, complications requiring medical intervention.
Apap Extra
The identified non-compliance in the form of the presence of a foreign body in the tablet may affect the safety of use of the medicinal product; a risk to human health and life cannot be excluded. Potential effects: mechanical damage, gastrointestinal complications, risk to health or life.
Clatra
The product does not meet quality requirements due to a negative test result for contamination with particles visible to the naked eye, which in sterile eye drops may pose a risk to the patient’s eye. Potential effects: eye irritation, mechanical damage, infection, ophthalmic complications.
Acurenal
suspected non-compliance with the specification for the parameter "impurity A content" in stability studies, including an OOS result for batch 80212781; after limit extension and toxicological assessment, no risk to the patient was confirmed. Potential effects: no or minimal health risk; the product remains effective.
Acurenal
In stability testing for the “impurity A content” parameter, an out-of-specification (OOS) result was obtained relative to the original specification, requiring a change of the limit in the product quality specification, although it was assessed not to pose a risk to patients. Potential effects: no significant health effects; the product remains effective and safe.
Angeliq
The medicinal product was released to the market with an outdated version of the patient leaflet; a health risk cannot be excluded due to information inconsistent with the approved documentation. Potential effects: incorrect use of the drug, lack of treatment efficacy, complications or increased adverse reactions.
Angeliq
It was found that an outdated version of the patient leaflet was included with batch KT0SLCS, so information on use, safety and adverse reactions does not meet current requirements. Potential effects: improper use of the medicine, lack of efficacy, increased risk of adverse reactions or complications.
Triacyt MR
The incorrect leaflet attached to batch 250202 does not contain updated information on the possibility of severe cutaneous adverse reactions during trimetazidine dihydrochloride use, which may affect treatment safety. Potential effects: severe skin reactions, complications, improper use of the medicine.
What to do if you bought a recalled product?
If you have purchased any of the products listed above, stop using or consuming them immediately. You can return the product to the store where you bought it for a full refund. Keep the receipt if possible, but most stores will accept returns even without one.